392 related articles for article (PubMed ID: 32819114)
1. Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
Dawood S; Konstantinova M; Perazzo F; Kim SB; Villarreal-Garza C; Franco SX; Simon SD; El-Nahas T
Chin Clin Oncol; 2020 Oct; 9(5):61. PubMed ID: 32819114
[TBL] [Abstract][Full Text] [Related]
2. Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting.
Dawood S; Konstantionva M; Dent R; Perazzo F; Kim SB; Villarreal-Garza C; Franco S; Dai MS; Simon S
BMC Proc; 2021 Aug; 15(Suppl 10):15. PubMed ID: 34372853
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Wang X; Shi Y; Huang D; Guan X
Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
[TBL] [Abstract][Full Text] [Related]
5. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L; Keyomarsi K
Expert Opin Investig Drugs; 2022 Jun; 31(6):607-631. PubMed ID: 35435784
[TBL] [Abstract][Full Text] [Related]
7. New agents for the management of resistant metastatic breast cancer.
Anampa J; Sparano JA
Expert Opin Pharmacother; 2017 Dec; 18(17):1815-1831. PubMed ID: 29171761
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
[TBL] [Abstract][Full Text] [Related]
9. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
11. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
Miller RS; Mokiou S; Taylor A; Sun P; Baria K
Breast Cancer Res Treat; 2022 May; 193(1):83-94. PubMed ID: 35194731
[TBL] [Abstract][Full Text] [Related]
12. PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.
Collet L; Péron J; Penault-Llorca F; Pujol P; Lopez J; Freyer G; You B
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158866
[TBL] [Abstract][Full Text] [Related]
13. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
14. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Tung NM; Robson ME; Ventz S; Santa-Maria CA; Nanda R; Marcom PK; Shah PD; Ballinger TJ; Yang ES; Vinayak S; Melisko M; Brufsky A; DeMeo M; Jenkins C; Domchek S; D'Andrea A; Lin NU; Hughes ME; Carey LA; Wagle N; Wulf GM; Krop IE; Wolff AC; Winer EP; Garber JE
J Clin Oncol; 2020 Dec; 38(36):4274-4282. PubMed ID: 33119476
[TBL] [Abstract][Full Text] [Related]
15. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
[TBL] [Abstract][Full Text] [Related]
16. Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors.
Vaid AK; Deshmukh C; Rohatgi N; Ghosh J
Indian J Cancer; 2022 Mar; 59(Supplement):S130-S141. PubMed ID: 35343197
[TBL] [Abstract][Full Text] [Related]
17. Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
Liede A; Sebby W; Miriyala AKR; Potluri R; Mazumder D; Ghosh A; Papademetriou E; Kilpatrick R; Tyczynski JE
BMC Cancer; 2023 Jan; 23(1):78. PubMed ID: 36690978
[TBL] [Abstract][Full Text] [Related]
18. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
20. Landmark trials in the medical oncology management of metastatic breast cancer.
Lu P; Santa-Maria CA; Ballinger TJ; Sheng JY
Semin Oncol; 2021 Jun; 48(3):246-258. PubMed ID: 34364700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]